PICO Advisory Sub-Committee (PASC) – Applications scheduled to be considered

• 1752 – Anal human papillomavirus (HPV) and cytology testing in high-risk populations to determine access to high-resolution anoscopy and ablative treatment to prevent anal cancer
• 1779 – Testing of tumour tissue to detect FGFR2 fusions or rearrangements in people with cholangiocarcinoma, to determine eligibility for treatment with PBS subsidised futibatinib
• 1781 – Risk assessment in prostate cancer using the Stockholm3 multiparametric blood test
• 1782 – Genetic testing to detect estrogen receptor 1 (ESR1) mutations in patients with estrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer, to determine eligibility for treatment with PBS subsidised elacestrant
• 1783 – Genetic testing to detect PIK3CA mutations in patients with hormone receptor (HR)-positive, HER-2 negative, locally advanced or metastatic breast cancer, to determine eligibility for treatment with PBS subsidised inavolisib

Consultation Input:

MSAC values consultation input from individuals and organisations with an interest in an application that it is considering, including experience of the medical conditions, services or technologies being addressed by the application.

Consultation for the August 2024 PASC meeting closes on Friday 12 July 2024.

Further information on MSAC’s consultation process is available on the MSAC website.